{"id":59333,"date":"2024-02-28T05:52:45","date_gmt":"2024-02-28T05:52:45","guid":{"rendered":"https:\/\/medsname.com\/torvate\/"},"modified":"2026-04-30T10:23:59","modified_gmt":"2026-04-30T10:23:59","slug":"torvate","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/torvate\/","title":{"rendered":"Torvate"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Snabbt svar<\/h3>\n

Torvate (Sodium valproate 200 \/ 300 \/ 500 mg) is an anticonvulsant and mood stabiliser used for epilepsy, bipolar mania, and migraine prophylaxis. Absolute contraindication in pregnancy and women of childbearing potential without strict pregnancy-prevention measures<\/strong> \u2014 high teratogenicity and neurodevelopmental risk.<\/p>\n<\/div>\n

\nVad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade kundrecensioner<\/a>\n<\/div>\n

\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n

Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n

Torvate at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20 arbetsdagar leveranstid eller vi skickar om utan extra kostnad \u2014 och kvalificerar sig f\u00f6r v\u00e5rt kundlojalitetsprogram<\/a>. V\u00e4rldsomsp\u00e4nnande leverans \u00e4r tillg\u00e4nglig till de flesta destinationer.<\/p>\n

What Torvate is and how it works<\/h2>\n

Torvate is a sodium valproate tablet supplied by Torrent. Available strengths: 200 \/ 300 \/ 500 mg<\/strong>. Valproate is a broad-spectrum anticonvulsant whose anti-seizure mechanisms include sodium-channel blockade, T-type calcium-channel modulation, and increased GABA availability. The anti-manic mechanism is poorly understood but well-evidenced in trials.<\/p>\n

\nPregnancy \u2014 absolute contraindication outside epilepsy<\/strong><\/p>\n

Valproate is one of the most teratogenic medications in routine use.<\/strong> First-trimester exposure produces neural tube defects (~ 1\u20132% absolute risk), cardiac and skeletal malformations, and a substantial reduction in childhood IQ (mean 7\u201310 points lower at age 6). UK MHRA, EMA, and FDA all require strict pregnancy-prevention programmes for women of childbearing potential. Outside refractory epilepsy where no alternative exists, do not initiate or continue valproate in any woman of childbearing potential without effective contraception and a pregnancy-prevention programme<\/strong>. Switch to lithium, lamotrigine, or an atypical antipsychotic for bipolar maintenance in pre-menopausal women.<\/p>\n<\/div>\n

Indikationer och dosering<\/h2>\n\n\n\n\n\n\n\n\n\n
Indikation<\/th>\nStartdos<\/th>\nM\u00e5lgrupp<\/th>\nTarget level<\/th>\n<\/tr>\n<\/thead>\n
Generalised epilepsy<\/td>\n10\u201315 mg\/kg\/day in 2 doses<\/td>\n20\u201360 mg\/kg\/day<\/td>\n50\u2013100 \u00b5g\/mL<\/td>\n<\/tr>\n
Bipolar mania (acute)<\/td>\n20\u201330 mg\/kg\/day in 2 doses<\/td>\n20\u201360 mg\/kg\/day<\/td>\n50\u2013125 \u00b5g\/mL<\/td>\n<\/tr>\n
Bipolar maintenance<\/td>\n\u2014<\/td>\n500\u20132500 mg\/day<\/td>\n50\u2013100 \u00b5g\/mL<\/td>\n<\/tr>\n
Migr\u00e4nprofylax<\/td>\n250 mg BID<\/td>\n500\u20131500 mg\/day<\/td>\n\u2014<\/td>\n<\/tr>\n
\u00c4ldre vuxna \/ leverskador<\/td>\nhalvera dosen<\/td>\n\u2014<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Viktiga s\u00e4kerhets\u00f6verv\u00e4ganden<\/h2>\n
\nHepatotoxicitet<\/strong><\/p>\n

Idiosyncratic fatal hepatitis is a recognised valproate complication, highest risk in children < 2 years on polytherapy. Mandatory baseline LFTs and recheck at 3 months, 6 months, then yearly. Stop immediately for jaundice, hepatomegaly, RUQ pain, or unexplained AST\/ALT > 3\u00d7 ULN.<\/p>\n<\/div>\n

\nPancreatitis (rare)<\/strong><\/p>\n

Acute haemorrhagic pancreatitis described, including paediatric fatal cases. Stop for unexplained abdominal pain, vomiting, anorexia.<\/p>\n<\/div>\n

\nHyperammonaemia<\/strong><\/p>\n

Valproate inhibits the urea cycle; hyperammonaemia can occur even with normal LFTs and produces drowsiness, confusion, and (rarely) encephalopathy. Check ammonia in patients with new lethargy or cognitive change.<\/p>\n<\/div>\n

\nPolycystic ovary syndrome and metabolic effects<\/strong><\/p>\n

Long-term valproate is associated with weight gain, insulin resistance, and PCOS in young women \u2014 another reason to prefer alternatives in pre-menopausal women.<\/p>\n<\/div>\n

\nThrombocytopenia and platelet dysfunction<\/strong><\/p>\n

Mild thrombocytopenia is common; check FBC at baseline, 3 months, 6 months. Significant thrombocytopenia is rare.<\/p>\n<\/div>\n

Vanliga biverkningar<\/h2>\n